Login to Your Account



Escape velocity? Bioblast phase II could open door to remedy in rare OPMD

By Randy Osborne
Staff Writer

Wednesday, March 16, 2016

Bioblast Pharma Ltd. CEO Colin Foster told BioWorld Today "it would not be unreasonable to think" that regulators could deem pivotal the upcoming phase IIb trial with trehalose in oculopharyngeal muscular dystrophy, but the company doesn't count on that.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription